555 related articles for article (PubMed ID: 31718684)
1. Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies.
Baci D; Bruno A; Cascini C; Gallazzi M; Mortara L; Sessa F; Pelosi G; Albini A; Noonan DM
J Exp Clin Cancer Res; 2019 Nov; 38(1):464. PubMed ID: 31718684
[TBL] [Abstract][Full Text] [Related]
2. Acetyl-l-carnitine is an anti-angiogenic agent targeting the VEGFR2 and CXCR4 pathways.
Baci D; Bruno A; Bassani B; Tramacere M; Mortara L; Albini A; Noonan DM
Cancer Lett; 2018 Aug; 429():100-116. PubMed ID: 29678548
[TBL] [Abstract][Full Text] [Related]
3. Sea cucumber extract TBL-12 inhibits the proliferation, migration, and invasion of human prostate cancer cells through the p38 mitogen-activated protein kinase and intrinsic caspase apoptosis pathway.
Yuan L; Huang X; Zhou K; Zhu X; Huang B; Qiu S; Cao K; Xu L
Prostate; 2019 Jun; 79(8):826-839. PubMed ID: 30889629
[TBL] [Abstract][Full Text] [Related]
4. Prostate Cancer Peripheral Blood NK Cells Show Enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 Production and Secrete Monocyte-Recruiting and Polarizing Factors.
Gallazzi M; Baci D; Mortara L; Bosi A; Buono G; Naselli A; Guarneri A; Dehò F; Capogrosso P; Albini A; Noonan DM; Bruno A
Front Immunol; 2020; 11():586126. PubMed ID: 33569050
[TBL] [Abstract][Full Text] [Related]
5. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow-derived mesenchymal stem cells induced by inflammatory cytokines produce angiogenetic factors and promote prostate cancer growth.
Yang KQ; Liu Y; Huang QH; Mo N; Zhang QY; Meng QG; Cheng JW
BMC Cancer; 2017 Dec; 17(1):878. PubMed ID: 29268703
[TBL] [Abstract][Full Text] [Related]
7. Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells.
Maxwell PJ; Neisen J; Messenger J; Waugh DJ
Oncotarget; 2014 Jul; 5(13):4895-908. PubMed ID: 24970800
[TBL] [Abstract][Full Text] [Related]
8. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
Liu X; Peng J; Sun W; Yang S; Deng G; Li F; Cheng JW; Gordon JR
Tohoku J Exp Med; 2012 Oct; 228(2):147-56. PubMed ID: 23019013
[TBL] [Abstract][Full Text] [Related]
9. Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA).
Reddy KRK; Dasari C; Duscharla D; Supriya B; Ram NS; Surekha MV; Kumar JM; Ummanni R
Angiogenesis; 2018 Feb; 21(1):79-94. PubMed ID: 29150732
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory mediators of prostate epithelial cells stimulated with Trichomonas vaginalis promote proliferative and invasive properties of prostate cancer cells.
Han IH; Kim JH; Jang KS; Ryu JS
Prostate; 2019 Jul; 79(10):1133-1146. PubMed ID: 31050003
[TBL] [Abstract][Full Text] [Related]
11. Angiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling.
Deep G; Gangar SC; Rajamanickam S; Raina K; Gu M; Agarwal C; Oberlies NH; Agarwal R
PLoS One; 2012; 7(4):e34630. PubMed ID: 22514647
[TBL] [Abstract][Full Text] [Related]
12. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis.
Arya M; Patel HR; McGurk C; Tatoud R; Klocker H; Masters J; Williamson M
J Exp Ther Oncol; 2004 Dec; 4(4):291-303. PubMed ID: 15844659
[TBL] [Abstract][Full Text] [Related]
13. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells.
Ferrer FA; Miller LJ; Andrawis RI; Kurtzman SH; Albertsen PC; Laudone VP; Kreutzer DL
Urology; 1998 Jan; 51(1):161-7. PubMed ID: 9457313
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 and CXCL12 (SDF-1) in prostate cancer: inhibitory effects of human single chain Fv antibodies.
Vaday GG; Hua SB; Peehl DM; Pauling MH; Lin YH; Zhu L; Lawrence DM; Foda HD; Zucker S
Clin Cancer Res; 2004 Aug; 10(16):5630-9. PubMed ID: 15328206
[TBL] [Abstract][Full Text] [Related]
16. FOXA1 promotes prostate cancer angiogenesis by inducing multiple pro-angiogenic factors expression.
Su Y; Zhang Y; Zhao J; Zhou W; Wang W; Han B; Wang X
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3225-3243. PubMed ID: 34258652
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer.
Heidegger I; Fotakis G; Offermann A; Goveia J; Daum S; Salcher S; Noureen A; Timmer-Bosscha H; Schäfer G; Walenkamp A; Perner S; Beatovic A; Moisse M; Plattner C; Krogsdam A; Haybaeck J; Sopper S; Thaler S; Keller MA; Klocker H; Trajanoski Z; Wolf D; Pircher A
Mol Cancer; 2022 Jun; 21(1):132. PubMed ID: 35717322
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer.
Kosaka T; Miyajima A; Takayama E; Kikuchi E; Nakashima J; Ohigashi T; Asano T; Sakamoto M; Okita H; Murai M; Hayakawa M
Prostate; 2007 Jan; 67(1):41-9. PubMed ID: 17044086
[TBL] [Abstract][Full Text] [Related]
19. Molecular targets for green tea in prostate cancer prevention.
Adhami VM; Ahmad N; Mukhtar H
J Nutr; 2003 Jul; 133(7 Suppl):2417S-2424S. PubMed ID: 12840218
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.
Maxwell PJ; Coulter J; Walker SM; McKechnie M; Neisen J; McCabe N; Kennedy RD; Salto-Tellez M; Albanese C; Waugh DJ
Eur Urol; 2013 Aug; 64(2):177-88. PubMed ID: 22939387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
